Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Use ProtoArray Platform in Research Collaboration with FSMA

NEW YORK, Dec. 21 (GenomeWeb News) - Invitrogen will use its ProtoArray protein microarrays in a collaboration with Families of Spinal Muscular Atrophy to identify biological targets associated with spinal muscular atrophy, the organizations said today.

 

SMA is a genetic disorder that causes a chronic deficiency in the production of the survival motor neuron (SMN) protein.

 

Invitrogen scientists will use the ProtoArray technology to screen approximately 3,000 human proteins and 5,000 yeast proteins as potential targets for SMA therapeutic intervention. The work builds upon the identification of compounds that up-regulate SMN levels in an FSMA-sponsored program at DeCode Genetics, FSMA said.

 

"We hope that the discovery and characterization of critical protein targets and their associated pathways will lead to new drug discovery avenues and ultimately to novel therapeutic approaches to treat SMA," said Jill Jarecki, research director of FSMA, in a statement.

 

The organizations said that the initial target identification stage will be followed by "further collaborative work to validate the targets and develop new compound screening assays."

 

Financial terms of the collaboration were not disclosed.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.